Differences and price comparison between domestic and imported drugs of Momelotinib

Molotinib is an oral small molecule JAK1/JAK2 inhibitor, mainly used to treat primary and secondary myelofibrosis (MF), which can improve anemia, splenomegaly and systemic symptoms. At present, molotinib has not been officially launched in China. If patients need to use it, they must obtain it through formal overseas channels to ensure the quality and safety of the drug.

The overseas US version of the original drug molotinib is consistent with clinical studies in terms of ingredients and efficacy, and its efficacy and safety are fully supported by data. However, it is expensive, with the latest market price of about more than 200,000 yuan. Imported drugs have stable quality and strict supervision, and are suitable for patients with high efficacy requirements and economic conditions. However, long-term use costs are high.

Lucious’s generic version of molotinib has been approved for marketing by the Ministry of Health of Laos. Its pharmaceutical ingredients are basically the same as the original drug, and its efficacy is theoretically comparable to that of the original drug. The specification is 100mg*30 tablets, and the price is about 2,000 yuan, which is much lower than the original drug. This type of generic drugs provides a viable option for patients who cannot afford the high cost of imported drugs, and also facilitates clinical promotion.

When choosing molotinib, patients and doctors need to make decisions based on economic conditions, medication needs and safety. If economic conditions permit and long-term efficacy is important, you can choose original imported drugs; if you want to reduce the cost of medication, you can consider generic drugs from formal channels. At the same time, doctors' instructions should be strictly followed during use, and blood and liver function should be monitored regularly to ensure stable and safe efficacy and avoid the occurrence of adverse events.

Reference materials:https://www.drugs.com/